The present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist, wherein the histamine-3 receptor inverse agonist is selected from N-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; N-[4-(1-cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; and N-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; or a pharmaceutically acceptable salt thereof; the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof; and the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof. Furthermore, the present invention relates to histamine-3 receptor (H3R) inverse agonist or pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and N-methyl-D-aspartate (NMDA) receptor antagonist and their use in the treatment of cognitive disorders. The present invention also relates to a pharmaceutical composition containing the said combination.
TRIPLE COMBINATION OF HISTAMINE-3 RECEPTOR INVERSE AGONISTS, ACETYLCHOLINESTERASE INHIBITOR AND NMDA RECEPTOR ANTAGONIST